Mesalazine Suppositories versus Hydrocortisone Foam in Patients with Distal Ulcerative Colitis:A Comparison of the Efficacy and Practicality of Two Topical Treatment Regimens

References

• Truelove S C. Treatment of ulcerative colitis with local hydrocortisone hemisuccinate sodium. A report on a controlled therapeutic trial. Br Med J 1958; 2: 1072–7
   PubMed Web of Science ®Google Scholar
• Azad Khan A K, Piris J, Truelove S C. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977; 2: 892–5
   PubMed Web of Science ®Google Scholar
• van Hees P AM, Bakker J H, van Tongeren J HM. Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopatic proctitis: a study to determine the active therapeutic moiety of sulphasalazine. Gut 1980; 21: 632–5
   PubMed Web of Science ®Google Scholar
• Danish 5-ASA Group. Topical 5-aminosalicylic acid versus prednisolone in ulcerative proctosigmoiditis. A randomized, double-blind multicenter trial. Dig Dis Sci 1987; 32: 598–602
   PubMed Web of Science ®Google Scholar
• Campieri M, Gionchetti P, Belluzzi A, et al. Efficacy of 5-aminosalicylic acid enemas versus hydrocortisone enemas in ulcerative colitis. Dig Dis Sci 1987; 32: 67S–70S, December Suppl
   Web of Science ®Google Scholar
• Campieri M, Lanfranchi G A, Bazzocchi G, et al. Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid. Lancet 1981; 2: 270–1
   PubMed Web of Science ®Google Scholar
• Sutherland L R, Martin F, Greer S, et al. 5-aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987; 92: 1894–8
   PubMed Web of Science ®Google Scholar
• Campieri M, Gionchetti P, Belluzzi A, et al. 5-aminosalicylic acid as enemas or suppositories in distal ulcerative colitis?. J Clin Gastroenterol 1988; 10: 406–9
   PubMed Web of Science ®Google Scholar
• Williams C N, Haber G, Aquino J A. Double-blind, placebo-controlled evaluation of 5-ASA suppositories in active distal proctitis and measurement of extent of spread using 99mrelabeled 5-ASA suppositories. Dig Dis Sci December, 1987; 32(Suppl)71S–5S
   PubMedGoogle Scholar
• Ruddell W SJ, Dickinson R J, Dixon M F, Axon A TR. Treatment of distal ulcerative colitis (proctosigmoiditis) in relapse: comparison of hydrocortisone enemas and rectal hydrocortisone foam. Gut 1980; 21: 885–9
   PubMed Web of Science ®Google Scholar
• Campieri M, Gionchetti P, Belluzzi A, et al. Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis. Gut 1991; 32: 929–31
   PubMed Web of Science ®Google Scholar
• Campieri M, de Franchis R, Bianchi Porro G, Ranzi T, Brunetti G, Barbara L. Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. A randomized controlled trial. Scand J Gastroenterol 1990; 25: 663–8
   PubMed Web of Science ®Google Scholar
• The Danish Budesonide Study Group. Budesonide enema in distal ulcerative colitis. A randomized dose-response trial with prednisolone enema as positive control. Scand J Gastroenterol 1991; 26: 1225–30
   PubMed Web of Science ®Google Scholar
• Danielsson Å, Hellers G, Lyrenas E, Lofberg R, Nilsson A, Olsson O, et al. A controlled randomized trial of budesonide versus prednisolone retension enemas in active distal ulcerative colitis. Scand J Gastroenterol 1987; 22: 987–92
   PubMed Web of Science ®Google Scholar
• Danielsson Å, Löfberg R, Persson T, Salde L, Schioler R, Suhr O, et al. A steroid enema, budesonide, lacking systemic effects for the treatment of distal ulcerative colitis or proctits. Scand J Gastroenterol 1992; 27: 9–12
   PubMed Web of Science ®Google Scholar
• Löfberg R, Östergaard-Thomsen O, Langholtz E, et al. Budesonide versus prednisolone enema in active distal ulcerative colitis. A comparative eight week study. Gut 1993; 34(Suppl 1)S41
   PubMedGoogle Scholar
• Lamers C, Meijer J, Engels L, et al. Comparative study of the topically acting glucocorticosteroid budesonide and 5-aminosalicylic acid enema therapy of proctitis and proctosigmoiditis. Gastroenterology 1991; 100: A 223
   Google Scholar
• Jay M, Diginis G A, Foster T S, Antonow D R. Retrograde spreading of hydrocortisone enema in inflammatory bowel disease. Dig Dis Sci 1986; 31: 139–44
   PubMed Web of Science ®Google Scholar
• Farthing M JG, Rutland M D, Clark M L. Retrograde spread of hydrocortisone containing foam given intrarectally in ulcerative colitis. Br Med J 1979; 2: 822–4
   PubMed Web of Science ®Google Scholar
• Sommerville K W, Langman M JS, Kane S P, MacGilchrist A J, Watkinson G, Salmon P. Effect of treatment on symptoms and quality of life in patients with ulcerative colitis: comparative trial of hydrocortisone acetate foam and prednisolone 21-phosphate enemas. Br Med J 1985; 291: 866
   PubMedGoogle Scholar
• Friedman L S, Richter J M, Kirkham S E, DeMonaco H J, May R J. 5-Aminosalicylic acid enemas in refractory distal ulcerative colitis: a randomized, controlled trial. Am J Gastroenterol 1986; 81: 412–8
   PubMed Web of Science ®Google Scholar
• Ngô Y, Rambaud J C. Lavement d'acid 5-aminosalicylique (Pen-tasa) versus mousse d'acétate d'hydrocortisone (Proctocort) dans le traitement des poussées de rectite et rectosigmoïdite cryptogénétique. Essai comparatif randomisé multicentrique. Gastroenterol Clin Biol 1992; 16: 558–63
   PubMedGoogle Scholar
• Pullan R D, Ganesh S, Mani V, et al. Comparison of bismuth citrate and 5-aminosalicylic acid enemas in distal ulcerative colitis: a controlled trial. Gut 1993; 34: 676–9
   PubMed Web of Science ®Google Scholar
• Tarpila S, Turunen U, Seppälä K, Autcee S, Pikkareinen P, Elomaa I, et al. Budesonide enema is as effective as hydrocortisone foam in proctitis [abstract]. Scand J Gastroenterol 1991; 26(Suppl 183)81
   Google Scholar
• Farup P G. Compliance with anti-ulcer medication during short-term healing phase clinical trials. Aliment Pharmacol Ther 1992; 6: 179–86
   PubMed Web of Science ®Google Scholar
• Jacobsen B A, Abildgaard K, Rasmussen H H, Christensen L A, Fallingborg J, Hansen S H, et al. Availability of mesalazine (5-aminosalicylic acid) from enemas and suppositories during steady-state conditions. Scand J Gastroenterol 1991; 26: 374–8
   PubMed Web of Science ®Google Scholar
• Compston J E, Judd D, Crawley E O, et al. Osteoporosis in patients with inflammatory bowel disease. Gut 1987; 28: 410–5
   PubMed Web of Science ®Google Scholar